Stay updated with the latest healthcare breakthroughs, including Otsuka’s sibeprenlimab 24-month eGFR data in IgA nephropathy.
News|Articles|July 7, 2024
7 FDA Drug Decisions Anticipated Before the End of 2024
Author(s)Kevin Kunzmann
After a busy first half to 2024, a number of high-impact FDA decisions await the healthcare industry through December.
Advertisement
Advertisement
After a very busy first half of 2024 in the pharmaceutical pipeline, a number of high-interest and practice-implicative
Related to this article
Lindsay Ackerman, MD, and Chris Bunick, MD, PhD, discuss where topical PDE4 inhibitors fit in atopic dermatitis and how to measure skin and itch response.
Shannon C. Trotter, DO, and Mona Shahriari, MD, discuss burnout, people-pleasing, public speaking, and the real life behind physicians’ polished personas.
In PHINDER, IPF had the highest PVD-B65 mortality risk scores. Rali discusses why PH in ILD is missed and when to refer for right heart catheterization.
Parth Rali, MD, explains how the AHA/ACC A-through-E categories compare with ESC risk tiers and how hospitals can meet the class 1 PERT recommendation.
Colin Church, MBBS, PhD, discusses durable 6MWD and NT-proBNP signals in a TPIP open-label extension and what phase 3 needs to show next.
Colin Church, MBBS, PhD, discusses 24-month open-label extension data showing TPIP remains tolerable in patients with PH-ILD, with no new safety signals.
This segment of Nguyen's 2026 Fall Clinical Dermatology interview highlights key insights on early dermatology career strategies and other information.
Advertisement
Advertisement